AAV1/SERCA2a

BIOLOGICAL2 trials

Sponsors

Imperial College London, Sardocor Corp.

Conditions

Chronic Heart FailureHeart Failure With Preserved Ejection FractionHeart Failure, DiastolicPatients That Have Received a Left Ventricular Assist Device

Phase 1

Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction

RecruitingNCT06061549

Sardocor Corp.Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction

Start: 2023-08-24End: 2029-08-31Target: 10Updated: 2023-09-29

Phase 2

Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients With Chronic Heart Failure

TerminatedNCT00534703

Imperial College LondonChronic Heart Failure, Patients That Have Received a Left Ventricular Assist Device

Start: 2014-07-31End: 2015-09-30Updated: 2023-02-08

Related Papers

Rationale and design of MUSIC-HFpEF: a phase 1b, pilot trial evaluating the safety and pharmacodynamic effects of AAV1.SERCA2A in heart failure with preserved ejection fraction.

2026-01-17